Safety of High-Dose Naltrexone Treatment: Hepatic Transaminase Profiles Among Outpatients
Safety of High-Dose Naltrexone Treatment: Hepatic Transaminase Profiles Among Outpatients
复制标题
大剂量纳曲酮治疗的安全性：门诊患者的肝转氨酶概况
DOI：
10.1097/00002826-200603000-00004
复制
发表时间：
2006
影响因子：
1
通讯作者：
R. Remmel
中科院分区：
文献类型：
--
作者：
Suck;J. Grant;Gihyun Yoon;K. Williams;R. Remmel
目的：本研究旨在验证在限制非处方止痛药使用的情况下，长期大剂量口服纳曲酮（150mg /d）的肝脏安全性是可以接受的假设。方法：对41例连续门诊接受纳曲酮治疗的冲动控制障碍患者的资料进行分析。结果：平均治疗时间328天，纳曲酮平均剂量142 mg/d。纳曲酮组治疗前/治疗后平均天冬氨酸转氨酶和丙氨酸转氨酶水平分别为21.79/22.54和21.74/21.49 U（均在参考范围内）。结论：尽管研究范围有限，但这些发现支持了这样的假设，即对于其他健康的冲动控制障碍患者，限制服用对乙酰氨基酚、阿司匹林或非阿司匹林非甾体抗炎药（NSAID），长期使用大剂量口服纳曲酮是安全的。然而，还需要进一步的研究。
Objectives: This study was carried out to test the hypothesis that the hepatic safety profile of prolonged high-dose oral naltrexone (150 mg/d) is acceptable if over-the-counter analgesic use is restricted. Methods: Data from 41 consecutive outpatients with impulse-control disorder receiving naltrexone therapy were analyzed. Results: The mean treatment duration was 328 days and the mean naltrexone dose was 142 mg/d. Pretherapy/posttherapy mean aspartate transaminase and alanine transaminase levels in the naltrexone-alone group were 21.79/22.54 and 21.74/21.49 U, respectively (all within reference range). Conclusions: Although limited in scope, these findings support the hypothesis that long-term use of high-dose oral naltrexone is safe in otherwise healthy patients with impulse-control disorders who restrict their intake of acetaminophen, aspirin, or nonaspirin nonsteroidal anti-inflammatory drugs (NSAID). However, confirming studies are needed.